Knocking Down CDKN2A in 3D hiPSC-Derived Brown Adipose Progenitors Potentiates Differentiation, Oxidative Metabolism and Browning Process

Cells. 2023 Mar 10;12(6):870. doi: 10.3390/cells12060870.

Abstract

Human induced pluripotent stem cells (hiPSCs) have the potential to be differentiated into any cell type, making them a relevant tool for therapeutic purposes such as cell-based therapies. In particular, they show great promise for obesity treatment as they represent an unlimited source of brown/beige adipose progenitors (hiPSC-BAPs). However, the low brown/beige adipocyte differentiation potential in 2D cultures represents a strong limitation for clinical use. In adipose tissue, besides its cell cycle regulator functions, the cyclin-dependent kinase inhibitor 2A (CDKN2A) locus modulates the commitment of stem cells to the brown-like type fate, mature adipocyte energy metabolism and the browning of adipose tissue. Here, using a new method of hiPSC-BAPs 3D culture, via the formation of an organoid-like structure, we silenced CDKN2A expression during hiPSC-BAP adipogenic differentiation and observed that knocking down CDKN2A potentiates adipogenesis, oxidative metabolism and the browning process, resulting in brown-like adipocytes by promoting UCP1 expression and beiging markers. Our results suggest that modulating CDKN2A levels could be relevant for hiPSC-BAPs cell-based therapies.

Keywords: 3D culture; CDKN2A; UCP1; adipocytes; brown adipose progenitor; browning; human induced pluripotent stem cells; thermogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes, Brown / metabolism
  • Cell Differentiation
  • Cyclin-Dependent Kinase Inhibitor Proteins
  • Cyclin-Dependent Kinase Inhibitor p16* / metabolism
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Obesity / metabolism
  • Oxidative Stress

Substances

  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor Proteins

Grants and funding

This work was supported by grants from the National Research Agency (E.G.I.D, ANR-10-LABX-46 and ANR-17-CE14-0034), Institut Pasteur de Lille (grant CPER CTRL Melodie), Fondation pour la Recherche Médicale (grant EQU202103012732), INSERM, CNRS, Université de Lille, Métropole Européenne de Lille and Société Francophone du Diabète. This project was funded by the French Government (National Research Agency, hiPS-Adipospehres ANR, CE18-0006) and the University Cote d’Azur through the “Investments for the Future” programs LABEX SIGNALIFE ANR-11-LABX-0028-01 and IDEX UCAJedi ANR-15-IDEX-01.